ProKidney Corp.
NASDAQ:PROKBiotechnology
+$0.02 today
- Market cap
- $349.70M
- Beta
- 1.70
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$0.53
Volume 1.80M
Average 0.96M
PROK Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
ProKidney Corp.NASDAQ: PROK
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue dips below year-ago levels
Q1 FY2026 revenue of $226K fell 1.7% year over year, behind the +190.5% change in trailing-twelve-month revenue. Sequentially, it rose 0.4% from the prior quarter.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 3 analysts of $654.2K (-26.7%) for the fiscal year ending Dec 2026, a slowdown from the +1075.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $226K+0.4% QoQ
- Last fiscal yearDec 2025
- $893K+1075.0% YoY
- LTMMar 2026
- $889K+190.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -1.7% | -15.7% | -14.0 pp |
| 1 year | +1075.0% | -26.7% | -1101.7 pp |
| 3-year CAGR | — | +139.7% | — |
| 5-year CAGR | +207.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 893K USD
- Year-over-year change
- +1075.0%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 893K | +1075.0% |
| FY2024 | 2024-12-31 | 76K | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Revenue vs competitors
How PROK compares with its peers on the latest reported figures
- PROK's LTM Mar 2026 revenue of $889K is the 4th highest of the 7 companies compared; the peer median is $10M.
- Its year-over-year change of +190.5% is the highest of 4, against a peer median of +18.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $651.04M | +49.4% | +64.9% | |
| LTM Mar 2026 | $427.68M | +18.2% | +98.4% | |
| LTM Mar 2026 | $20M | -88.1% | — | |
| LTM Mar 2026 | $889K | +190.5% | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Dec 2024 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| Peer median (excluding PROK) | $10M | +18.2% | +81.6% | |
Competitors are the stored peer set for PROK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 76K | 893K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 76K | 893K |
| Gross Margin | — | — | — | 100.0% | 100.0% |
| Research & Development | 46.26M | 82.07M | 106.71M | 127.67M | 114.12M |
| Selling, General & Admin | 8.86M | 70.94M | 44.82M | 56.08M | 51.78M |
| Operating Expenses | 55.11M | 153.01M | 151.52M | 183.75M | 165.9M |
| Depreciation & Amortization | 1.98M | 3.04M | 3.85M | 5.43M | 6.58M |
| EBITDA | (53.12M) | (143.99M) | (125.59M) | (158.49M) | (144.62M) |
| EBITDA Margin | — | — | — | -208542.1% | -16194.7% |
| Operating Income | (55.11M) | (153.01M) | (151.52M) | (183.68M) | (165.01M) |
| Operating Margin | — | — | — | -241678.9% | -18477.8% |
| Interest Income | 2K | 5.98M | 22.08M | 19.75M | 13.81M |
| Interest Expense | 0 | 215K | 12K | 9K | 4K |
| Other Income / Expenses | 2K | 5.77M | 22.07M | 19.74M | 13.81M |
| Income Before Tax | (55.11M) | (147.24M) | (129.45M) | (163.93M) | (151.2M) |
| Pre-Tax Margin | — | — | — | -215701.3% | -16931.5% |
| Income Tax Expense | 38K | 896K | 6M | (598K) | 414K |
| Net Income | (55.15M) | (108.03M) | (35.47M) | (61.19M) | (68.99M) |
| Net Margin | — | — | — | -80507.9% | -7725.2% |
| EPS (Basic) | (1.73) | (1.76) | (0.57) | (0.62) | (0.52) |
| EPS (Diluted) | (1.73) | (1.76) | (0.57) | (0.62) | (0.52) |
| Weighted Avg Shares | 31.89M | 61.54M | 61.71M | 97.92M | 133.94M |
| Weighted Avg Shares (Diluted) | 31.89M | 61.54M | 61.71M | 97.92M | 133.94M |
ProKidney Corp.
NASDAQ:PROK
Intrinsic Alpha fair value
Locked
Current Price
$1.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.